- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03545672
Early Identification of Myocardial Impairment in PBC (EARLY-MYO-PBC)
EARLY Identification of MYOcardial Impairment in Primary Biliary Cholangitis
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Renji Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria for PBC group:
- Age between 18-80 years old.
Definite primary biliary cirrhosis diagnosis which is consistent with European Association for the Study of the Liver (EASL) [Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis (2017)]. The following three diagnostic factors, at least meet two:
- History of elevated alkaline phosphatase (ALP) levels;
- Liver biopsy consistent with PBC;
- Positive antimitochondrial antibodies (AMA) or specific antinuclear antibodies.
- Providing written informed consent
Exclusion Criteria:
History or presence of other concomitant liver disease including:
- Viral hepatitis;
- Inherited metabolic liver disease;
- Drug-induced liver injury;
- Other systemic disease inducing liver change.
- Subjects with known ischemic/non-ischemic cardiomyopathy.
- Subjects with standard metallic contraindications to CMR (i.e., estimated glomerular filtration rate < 30 ml/min/1.73 m2, New York Heart Association functional capacity class IV)
Inclusion Criteria for Control group:
- Absence of known systemic diseases
- Normal examinations in CMR/Echo/ECG
- Age between 18-80 years old.
- Providing written informed consent
Exclusion Criteria:
Subjects with known heart disease including:
- Documented coronary artery disease;
- Ischemia/non-ischemia cardiomyopathy;
- Other systemic disease inducing heart change.
Subjects with known liver disease including:
- Viral hepatitis;
- Inherited metabolic liver disease;
- Drug-induced liver injury;
- Other systemic disease inducing liver change.
- Subjects with standard metallic contraindications to CMR
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PBC group
Patients have a definite PBC diagnosis.
|
After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
|
Control group
The healthy volunteers or patients in Renji Hospital whose medical examinations show no systemic disease, and the CMR examinations are normal.
|
After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of cardiac involvement
Time Frame: through study completion, an average of 14 months
|
Assessments base on the cardiac structure, function and tissue characterization
|
through study completion, an average of 14 months
|
Composite endpoint of quantitative assessment in cardiac injury
Time Frame: within 2 days of CMR scan
|
Compose of extracellular volume(%), T1 value(ms) and T2 value(ms).
|
within 2 days of CMR scan
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite endpoint of liver condition
Time Frame: within 2 days of CMR scan
|
Compose of the alanine aminotransferase (ALT), Aspartate aminotransferase (AST) ,alkaline phosphatase (AKP) and bilirubin indicating the liver condition and prognosis.
|
within 2 days of CMR scan
|
Composite endpoint of cardiac function
Time Frame: within 2 days of CMR scan
|
Compose of CRP (hs-CRP), troponin I (TnI) and hematocrit indicating the cardiac function
|
within 2 days of CMR scan
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Xiong Ma, MD,PhD, RenJi Hospital, School of Medicine, Shanghai Jiantong University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201709P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Abnormalities
-
Ionis Pharmaceuticals, Inc.Akcea TherapeuticsCompletedAbnormalities, CardiovascularUnited States
-
University of California, DavisTerminatedAbnormalities, Cardiovascular
-
BayerCompleted
-
Soroka University Medical CenterCompletedCardiovascular Abnormalities | Hemodynamic Instability | Respiratory AbnormalitiesIsrael
-
Cliniques universitaires Saint-Luc- Université...CompletedCardiovascular AbnormalitiesBelgium
-
Medical College of WisconsinChildren's National Research InstituteCompleted
-
CargillAjinomoto Co., Inc.CompletedCardiovascular Abnormalities
-
Baylor Research InstituteActive, not recruiting
-
Washington University School of MedicineFoundation for Anesthesia Education and ResearchCompletedCardiovascular AbnormalitiesUnited States
-
Hoffmann-La RocheWithdrawnCardiovascular AbnormalitiesCanada
Clinical Trials on CMR examination
-
RenJi HospitalCompletedConnective Tissue Diseases | Right Ventricular HypertrophyChina
-
RenJi HospitalRuijin Hospital; Shanghai Fifth People's HospitalRecruitingBreast Cancer | Chemotherapy Induced Systolic DysfunctionChina
-
Karolinska InstitutetSwedish Medical Research CouncilCompletedMyocardial InfarctionSweden
-
Xiang Guang-daCompletedType 2 DiabetesChina
-
University of ZurichETH ZurichRecruitingNon ST Elevation Myocardial Infarction | Myocarditis Acute | Takotsubo Cardiomyopathy | Spontaneous Coronary Artery Dissection | Myocardial Infarction With Non-Obstructive Coronary ArterySwitzerland
-
Brigham and Women's HospitalCompleted
-
Radboud University Medical CenterUnknownBreast Cancer | Cardiotoxicity | Chemotherapy Induced Systolic DysfunctionNetherlands
-
NHS National Waiting Times Centre BoardBritish Heart Foundation; University of Glasgow; Chief Scientist Office of the...RecruitingCoronary Artery Disease | Angina, Stable | Angina Pectoris | Microvascular Angina | Non-Obstructive Coronary Atherosclerosis | Small Vessel Cerebrovascular DiseaseUnited Kingdom
-
Heinrich-Heine University, DuesseldorfRecruiting
-
NYU Langone HealthRecruiting